BioNTech's Q3 Slump and Q4 Upbeat Vaccine Projections
Surprising Quarterly Results Send Shockwaves through BioNTech Share Prices
BioNTech's revenue and earnings took a hit in Q3 as a supply agreement was rescheduled for Q4. From July to September, the biotech giant raked in 3.46 billion euros, a significant drop compared to the six billion in the same period last year. Net profit also plummeted from 3.21 billion euros to 1.78 billion. However, for the first nine months, overall profit stood just above last year's level at 7.15 billion euros.
This dip is partly attributable to a strong performance from BioNTech's Omicron-adapted vaccine. The German biotech company now projects a total revenue of 16 to 17 billion euros for its Covid-19 vaccine in 2022, instead of the previous 13 to 17 billion. So far, 300 million doses of the adapted vaccine have been billed, as per BioNTech.
Post Q3 results, BioNTech's stock slightly upticked, initially being in the red for the day.
A Peek into BioNTech Stock
With a P/E ratio of 3.6, BioNTech's stock is surprisingly affordable. However, investors should brace for the fact that the astronomical buzz generated by the mRNA vaccine against the corona virus has somewhat subsided. But the BioNTech stock still holds promising prospects in the long run.
Despite a potential increase in P/E ratio in the coming years as profits wane, this doesn't necessarily equate to a lower stock price. The current attractive valuation will likely adjust to a more typical level.
Eight analysts at Bloomberg advocate buying BioNTech stock, nine suggest holding onto it, and none advise selling. The average price target stands at 217 euros, offering around 41 percent upside potential.
Fun Fact: The BioNTech stock is part of the BÖRSE ONLINE Reversal Index. This index certificate with WKN DA0ABB includes ten stocks that could be poised for a comeback in the stock market.
Disclosure: The CEO and majority shareholder of the publisher Börsenmedien AG, Mr. Bernd Förtsch, has direct and indirect positions in the financial instruments mentioned in this publication, which could benefit from potential price changes resulting from the publication: BioNTech.
Disclosure: The editor-in-chief of this publication, Mr. Frank Pöpsel, has direct and indirect positions in the financial instruments mentioned in this publication, which could benefit from potential price changes resulting from the publication: BioNTech.
The financial instrument's price is derived from an index as the underlying. Börsenmedien AG has developed this index and holds the rights to it. Börsenmedien AG has entered into a cooperation agreement with the issuer of the displayed securities, granting them a license to use the index. In this arrangement, Börsenmedien AG receives remuneration from the issuer.
- Despite the slump in BioNTech's revenue and earnings during Q3, the biotech company still projects a total revenue of 16 to 17 billion euros for its Covid-19 vaccine in 2022, according to their Omicron-adapted vaccine performance.
- In the health-and-wellness sector, BioNTech's stock is considered quite affordable with a P/E ratio of 3.6, offering potential long-term growth for investors, despite the subsided buzz generated by its mRNA vaccine.
- The BioNTech stock, a part of the BÖRSE ONLINE Reversal Index, is poised for a comeback in the stock market, according to the index certificate with WKN DA0ABB.
- In terms of finance and investing, BioNTech's stock remains a subject of interest for investors, with eight analysts at Bloomberg advocating for buying, nine suggesting holding onto it, and none advising selling.
- The BioNTech stock's current attractive valuation, along with its promising prospects and average price target of 217 euros (offering around 41 percent upside potential), make it a significant financial instrument in the science and health-and-wellness sectors.
